Reduced Anticoagulation Targets in ECLS (RATE)

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

March 7, 2025

Study Completion Date

March 7, 2025

Conditions
Heart FailureRespiratory FailureExtracorporeal Membrane OxygenationBleedingThrombosis
Interventions
DRUG

Heparin

Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.

DRUG

LMWH

Administration of LMWH guided by weight and renal function during ECLS.

Trial Locations (8)

6525GA

Radboud UMC, Nijmegen

6229HX

Maastricht Universitair Medisch Centrum+, Maastricht

1091AC

OLVG, location East, Amsterdam

1100DD

Amsterdam UMC, location AMC, Amsterdam

8025AB

Isala Clinics, Zwolle

9700RB

University Medical Center Groningen, Groningen

2300RC

Leids Universitair Medisch Centrum, Leiden

3000CA

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Isala

OTHER

collaborator

OLVG

NETWORK

collaborator

Radboud University Medical Center

OTHER

lead

University Medical Center Groningen

OTHER

NCT04536272 - Reduced Anticoagulation Targets in ECLS (RATE) | Biotech Hunter | Biotech Hunter